T. Xi, M. Cotation, and T. , 82 T Ta ab bl le e d de es s m ma at ti iè èr re es s

R. Le-contexte, 10 I.3.3 Les enjeux économiques et pratiques : préparation à l'avance, gain de temps, économies, confort du patient et dosebanding

I. Stabilis® and .. , 35 III.3 King Guide to parenteral admixtures, ., p.36

I. La and .. De-donnees-stabilis-®, 38 IV.1 Historique et présentation de la base de données, p.38

.. Traduction-informatique, 51 I.3 3 ème phase : travail individuel de cotation des publications relatives aux études de stabilité des médicaments anticancéreux, 56 I.3.1 Inventaire des publications à, p.56

.. De-figure, 97 III.3.8 Mais où sont les produits de dégradation ?, III.3.7 D comme Différents cas, p.97

D. Larousse®, Définition de la stabilité Page consultée le 13 avril 2013

A. Duriez, J. Vigneron, H. Zenier, I. May, and B. Demoré, Stability of Azacitidine Suspensions, Annals of Pharmacotherapy, vol.41, issue.4, p.546, 2011.
DOI : 10.1345/aph.1P431

Y. Cheung, B. Vishnuvajjala, N. Morris, and K. Flora, Stability of azacitidine in infusion fluids

D. Hartigh, J. Brandenburg, H. Vermeij, and P. , Stability of azacitidine in lactated Ringer's injection frozen in polypropylene syringes, Am J Hosp Pharm, vol.46, pp.2500-2505, 1989.

D. Vidal®, Résumé des caractéristiques du produit Vidaza ®. 89 ème éd, p.2527

M. Paul, V. Vieillard, E. Roumi, A. Cauvin, M. C. Despiau et al., Long-term stability of bevacizumab repackaged in 1mL polypropylene syringes for intravitreal administration, Annales Pharmaceutiques Fran??aises, vol.70, issue.3, pp.139-154, 2012.
DOI : 10.1016/j.pharma.2012.03.006

M. Pujol, M. Munoz, J. Prat, V. Giona, D. Bolos et al., Stability Study of Epirubicin in Nacl 0.9% Injection, Annals of Pharmacotherapy, vol.8, issue.9, pp.992-995, 1997.
DOI : 10.1002/jps.2600510902

P. Adams, R. Haines-hutt, E. Bradford, A. Palmer, and C. Rowland, Pharmaceutical aspects of home infusion therapy for cancer patients, Pharm J, vol.238, pp.476-478, 1987.

M. Hrubisko, M. Gown, A. Prendiville, J. Radford, J. Thatcher et al., Suitability of cisplatin solutions for 14-day continuous infusion by ambulatory pump, Cancer Chemotherapy and Pharmacology, vol.2, issue.Suppl 3, pp.252-255, 1992.
DOI : 10.1007/BF00686261

M. Priston and G. Sewell, Stability of three cytotoxic drug infusions in the Graseby 9000 ambulatory infusion pump, Journal of Oncology Pharmacy Practice, vol.3, issue.3, pp.143-149, 1998.
DOI : 10.1177/107815529700300304

E. Nyhammar, S. Johansson, and B. Seiving, Stability of doxorubicin and vincristine sulfate in two portable infusion-pump reservoirs, Am J Health-Syst, vol.53, pp.1171-1173, 1996.

J. Beijnen, C. Neef, O. Meuwissen, J. Rutten, H. Rosing et al., Stability of intraveinous admixtures of doxorubicin and vincristine, Am J Hosp Pharm, vol.43, pp.3022-3027, 1986.

R. Trittler, Stability of intravenous admixtures of doxorubicin and vincristine confirmed by LC-MS

L. Trissel, D. Gilbert, and J. Martinez, Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration, Am J Health-Syst Pharm, vol.54, pp.56-60, 1997.

J. Stewart, F. Warren, D. King, and J. Fox, Stability of ondansetron hydrochloride and five antineoplasic medications, Am J Health-Syst Pharm, vol.53, pp.1297-1300, 1996.

J. Munson, E. Kubiak, and M. Cohon, Cytosine Arabinoside Stability in Intravenous Admixtures with Sodium Bicarbonate and in Plastic Syringes, Drug Intelligence & Clinical Pharmacy, vol.61, issue.10, pp.765-767, 1982.
DOI : 10.1002/jps.2600610803

J. Vigneron, Stability studies of drugs used in oncology: the role of the hospital pharmacists, EJHP Practice, vol.12, issue.6, pp.75-76, 2006.

J. Vigneron, A. Astier, R. Trittler, J. Hecq, M. Daouphars et al., SFPO and ESOP recommendations for the practical stability of anticancer drugs: An update, Annales Pharmaceutiques Fran??aises, vol.71, issue.6, p.2013
DOI : 10.1016/j.pharma.2013.06.002

J. Vigneron, S. Garnier, A. Delfour, I. May, and B. Demoré, Extended stability of rituximab, bortezomib and azacitidine : application in the daily practice in haematology, EJOP, vol.6, issue.2, pp.12-13, 2012.

D. Vidal®, Résumé des caractéristiques du produit Velcade®. 89 ème éd, p.2493

M. Perissutti, . Mémoire-du-des-de-pharmacie-hospitalière, and . Des-collectivités, Etude de la stabilité d'une solution de Bortezomib à 1 mg/mL conditionnée en seringue de polypropylène -Application à la production quotidienne d'une unité de production centralisée de préparation de cytotoxiques pour le service d'hospitalisation de jour d'Hématologie, 2011.

M. Giovanelli, Mémoire de DES Pharmacie-Etude de la stabilité d'une solution de bortezomib à 2, p.5

F. Pinguet, Guidelines for the pratical stability studies of anticancer drugs : A European consensus conference, Ann Pharm Fr, vol.69, pp.221-231, 2011.

M. Bakshi and S. Singh, Development of validated stability-indicating assay methods???critical review, Journal of Pharmaceutical and Biomedical Analysis, vol.28, issue.6, pp.1011-1040, 2002.
DOI : 10.1016/S0731-7085(02)00047-X

R. Maggio, S. Vignaduzzo, and T. Kaufman, Practical and regulatory considerations for stability-indicating methods for the assay of bulk drugs and drug formulations, TrAC Trends in Analytical Chemistry, vol.49, 2013.
DOI : 10.1016/j.trac.2013.05.008

P. Riddhiben, P. Piyushbhai, and P. Natubhai, Stability indicating HPLC method development ? a review

N. Rao, R. Nagaraju, and V. , An overview of the recent trends in development of HPLC methods for determination of impurities in drugs, J Pharm Biomed Anal, vol.33, pp.335-337, 2003.

D. Food and . Administration, Department of Health and Human Services. Guidance for Industry, Analytical Procedures and Method Validation, pp.25-2013, 2010.

R. Hagan, High-Performance liquid chromatography for small-scales studies of drug stability, Am J

E. Pharmacopeia, Essai 2.2.1 :Clarity and degree of opalescence of liquids, 517605.

E. Pharmacopeia, Essai 2.9.19. Particulate contamination: sub-visible particles, 21624.

Q. Xu and L. Trissel, Stability-indicating HPLC methods for drug analysis, p.904, 1999.

K. Connors, G. Amidon, and V. Stella, Chemical Stability of Pharmaceuticals : A Handbook for Pharmacists, p.864, 1986.

D. Jain and P. Kumar-bansiwal, Forced degradation and impurity profiling: Recent trends in analytical perspectives, Journal of Pharmaceutical and Biomedical Analysis, vol.86, pp.11-35, 2013.
DOI : 10.1016/j.jpba.2013.07.013

G. Ngwa, Forced Degradation an Integral Part of HPLC Stability-indicating Method Development

D. Reynolds, K. Facchine, J. Mullaney, K. Alsante, T. Hatajik et al., Available Guidance and Best Practices for Conducting Forced Degradation Studies, Pharm Technol, vol.26, issue.2, pp.48-56, 2002.

M. Swartz and I. Krull, Developing and validating Stability-Indicating Methods, LCGC North America, vol.23, issue.6, pp.586-593, 2005.

S. Baertschi, Analytical methodologies for discovering and profiling degradation-related impurities, TrAC Trends in Analytical Chemistry, vol.25, issue.8, pp.758-767, 2006.
DOI : 10.1016/j.trac.2006.05.012

S. Görög, The importance and the challenges of impurity profiling in modern pharmaceutical analysis, TrAC Trends in Analytical Chemistry, vol.25, issue.8, pp.755-757, 2006.
DOI : 10.1016/j.trac.2006.05.011

S. Görög, The role of analytical chemistry in drug-stability studies, TrAC Trends in Analytical Chemistry, vol.49, pp.55-56, 2013.
DOI : 10.1016/j.trac.2013.06.001

B. Olsen, B. Castle, and D. Myers, Advances in HPLC technology for the determination of drug impurities, TrAC Trends in Analytical Chemistry, vol.25, issue.8, pp.796-805, 2006.
DOI : 10.1016/j.trac.2006.06.005

J. Dolan, Stability-Indicating Assays, LCGC North America, vol.20, issue.4, pp.346-349, 2002.

M. Feinberg, Labostat Guide de validation des méthodes d'analyse, p.361

A. Eppler, M. Weigandt, A. Hanefeld, and H. Bunjes, Relevant shaking stress conditions for antibody preformulation development, European Journal of Pharmaceutics and Biopharmaceutics, vol.74, issue.2, pp.139-147, 2010.
DOI : 10.1016/j.ejpb.2009.11.005

M. Harris, Monoclonal antibodies as therapeutic agents for cancer, The Lancet Oncology, vol.5, issue.5, pp.292-302, 2004.
DOI : 10.1016/S1470-2045(04)01467-6

A. Lahlou, B. Blanchet, M. Carvalho, M. Paul, and A. Astier, Mechanically-induced aggregation of the monoclonal antibody cetuximab, Annales Pharmaceutiques Fran??aises, vol.67, issue.5, pp.340-352, 2009.
DOI : 10.1016/j.pharma.2009.05.008

M. Manning, D. Chou, B. Murphy, R. Payne, and D. Katayama, Stability of Protein Pharmaceuticals: An Update, Pharmaceutical Research, vol.74, issue.48, pp.544-575, 2010.
DOI : 10.1016/j.bbapap.2006.05.013

A. Daugherty and R. Mrsny, Formulation and delivery issues for monoclonal antibody therapeutics
DOI : 10.1007/978-0-387-76643-0_8

A. Chow, H. Tong, and Y. Zheng, Stability Assessment and Formulation Charaterization, Handbook of Pharmaceutical Biotechnology, p.1660, 2007.

W. Wang, S. Nema, and D. Teagarden, Protein aggregation???Pathways and influencing factors, International Journal of Pharmaceutics, vol.390, issue.2
DOI : 10.1016/j.ijpharm.2010.02.025

P. L. Privalov, Stability of Proteins Small Globular Proteins, Adv Protein Chem, vol.33, pp.167-241, 1979.
DOI : 10.1016/S0065-3233(08)60460-X

E. Freire, A. Schön, B. Hutchins, and K. Brown, Chemical denaturation as a tool in the formulation optimization of biologics, Drug Discovery Today, vol.18, issue.19-20, 2013.
DOI : 10.1016/j.drudis.2013.06.005

W. Jiskoot and D. Crommelin, What makes protein drugs different ? Pharmaceutical aspects, EJHP Practice, pp.20-21, 2006.

D. Crommelin and W. Jiskoot, What makes protein drugs different ? Some considerations of shifting paradigms in Pharmacy. EJHP Practice, pp.14-16, 2006.

W. Wang, Protein aggregation and its inhibition in biopharmaceutics, International Journal of Pharmaceutics, vol.289, issue.1-2, pp.1-30, 2005.
DOI : 10.1016/j.ijpharm.2004.11.014

J. Philo and T. Arakawa, Mechanisms of Protein Aggregation, Current Pharmaceutical Biotechnology, vol.10, issue.4, pp.348-351, 2009.
DOI : 10.2174/138920109788488932

R. Thorpe and M. Wadhwa, Protein Therapeutics and Their Immunogenicity. EJHP Practice, pp.17-18, 2006.

M. Kessler, D. Goldsmith, and H. Schellekens, Immunogenicity of biopharmaceuticals, Nephrology Dialysis Transplantation, vol.21, issue.suppl_5, pp.9-12, 2006.
DOI : 10.1196/annals.1313.027

H. Schellekens, Bioequivalence and the immunogenicity of biopharmaceuticals, Nature Reviews Drug Discovery, vol.13, issue.6, pp.457-462, 2002.
DOI : 10.1007/BF02990843

V. Filipe, W. Jiskoot, A. Basmeleh, A. Halim, H. Schellekens et al., Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice, mAbs, vol.102, issue.6, pp.740-752, 2012.
DOI : 10.1016/j.jim.2010.09.005

H. Schellekens, The immunogenicity of Therapeutics proteins, Discovery Medicine, vol.9, issue.49, pp.560-564, 2010.

T. Arakawa, S. Prestrelski, W. Kenney, and J. Carpenter, Factors affecting short-term and long-term stabilities of proteins, Advanced Drug Delivery Reviews, vol.46, issue.1-3, pp.307-326, 2001.
DOI : 10.1016/S0169-409X(00)00144-7

H. Ikesue, L. Vermeulen, R. Hoke, and J. Kolesar, Stability of cetuximab and panitumumab in glass vials and polyvinyl chloride bags, American Journal of Health-System Pharmacy, vol.67, issue.3, pp.223-226, 2010.
DOI : 10.2146/ajhp090031

Y. Zhang, L. Vermeulen, and J. Kolesar, Stability of stock and diluted rituximab, American Journal of Health-System Pharmacy, vol.70, issue.5, pp.436-438, 2013.
DOI : 10.2146/ajhp120035

M. Paul, V. Vieillard, E. Jaccoulet, and A. Astier, Long-term stability of diluted solutions of the monoclonal antibody rituximab, International Journal of Pharmaceutics, vol.436, issue.1-2, pp.282-290, 2012.
DOI : 10.1016/j.ijpharm.2012.06.063

I. Gindre, . Mémoire, and . De, Pharmacie Hospitalière et des Collectivités ? Création d'une base de données sur CD-Rom, conçue dans un langage international à base de pictogrammes, concernant la stabilité et la compatibilité des médicaments injectables, 2000.

L. Williams and M. Hastings, Identifying the criteria of a valid stability study, Int J Pharm Compound, vol.13, pp.32-36, 2009.

. Sfpo and . Stability, SFPO and ESOP recommendations for the practical stability of anticancer drugs, EJOP, vol.4, issue.3, pp.7-10, 2010.

T. Dine, M. Luyckx, J. Cazin, F. Goudaliez, and M. Mallevais, Stability and compatibility studies of vinblastine, vincristine, vindesine and vinorelbine with PVC infusion bags, International Journal of Pharmaceutics, vol.77, issue.2-3, pp.279-285, 1991.
DOI : 10.1016/0378-5173(91)90328-L

G. Sewell, C. Riley, and C. Rowland, THE STABILITY OF CARBOPLATIN IN AMBULATORY CONTINUOUS INFUSION REGIMES, Journal of Clinical Pharmacy and Therapeutics, vol.44, issue.6, pp.427-432, 1987.
DOI : 10.1097/00000421-198510000-00017

G. Sesin, L. Millette, and B. Weiner, Stability study of 5-fluorouracil following repackaging in plastic disposable syringes and multidose vials, Am J IV Ther Clin Nut, vol.9, pp.23-25, 1982.

K. Fredriksson, P. Lundgren, and L. Landersjo, Stability of carmustine -kinetics and compatibility during administration, Acta Pharm Suec, vol.23, pp.115-124, 1986.

M. Allwood and H. Martin, The extraction of diethylhexylphtalate (DEHP) from polyvinyl chloride components of intravenous infusion containers and administration sets by paclitaxel injection, Int J

S. Pearson and L. Trissel, Leaching of diethylhexyl phthalate from polyvinyl chloride containers by selected drugs and formulation components, Am J Hosp Pharm, vol.50, pp.1405-1409, 1993.

L. Trissel, Q. Xu, J. Kwan, and J. Martinez, Compatibility of paclitaxel injection vehicle with intravenous administration and extension sets, Am J Hosp Pharm, vol.51, pp.2804-2810, 1994.

D. Mazzo, J. Nguyen-huu, S. Pagniez, and P. Denis, Compatibility of docetaxel and paclitaxel in intravenous solutions with polyvinyl chloride infusion materials, Am J Health-Syst Pharm, vol.54, pp.566-569, 1997.

W. Waugh, L. Trissel, and V. Stella, Stability, compatibility, and plasticizer extraction of taxol (NSC- 125973) injection diluted in infusion solutions and stored in various containers, Am J Hosp Pharm, vol.48, pp.1520-1524, 1991.

S. Kim, H. Yoon, J. Lee, Y. J. Park, E. et al., Investigation of the release behavior of DEHP from infusion sets by paclitaxel-loaded polymeric micelles, International Journal of Pharmaceutics, vol.293, issue.1-2, pp.303-310, 2005.
DOI : 10.1016/j.ijpharm.2005.01.011

V. Corbrion, S. Crauste-manciet, P. Allain, and D. Brossard, Precipitation of fluorouracil in elastomeric infusers with a polyisoprene reservoir and in polypropylene syringes with an elastomeric joint, Am J Health-Syst Pharm, vol.54, pp.1845-1848, 1997.

M. Allwood, Fluorouracil precipitate, Am J Health-Syst Pharm, vol.55, pp.1315-1316, 1998.

M. Colvin and J. Hartner, Summerfield M, Stability of carmustine in the presence of sodium bicarbonate

S. Manners, P. Galettis, D. Souza, and P. , Conditions causing gemcitabine crystallization, Journal of Oncology Pharmacy Practice, vol.5, issue.4, pp.395-399, 2011.
DOI : 10.1016/j.urology.2004.08.027

S. Chang, T. Evans, and D. Alberts, The stability of melphalan in the presence of chloride ion???, Journal of Pharmacy and Pharmacology, vol.4, issue.1
DOI : 10.1007/978-1-4684-1378-6_5

R. Respaud, L. Quenum, C. Plichon, J. Tournamille, E. Gyan et al., A stability-indicating, ion-pairing, reversed-phase liquid chromatography method for studies of daunorubicin degradation in i.v. infusion fluids, Journal of Pharmaceutical and Biomedical Analysis, vol.83, pp.164-170, 2013.
DOI : 10.1016/j.jpba.2013.05.007

M. Paul, V. Vieillard, E. Jaccoulet, and A. Astier, Physicochemical and biological stability of diluted rituximab solutions stored 6 months at 4°C. Congrès ECCO, 2011.

O. Nicolson, B. Hayer, V. Vieillard, S. Dollet, A. Astier et al., Stability of diluted L-asparaginase in normal saline solution. Congrès ECCO, 2011.

J. Kaiser and I. Kramer, Physicochemical Stability of Diluted Trastuzumab Infusion Solutions in Polypropylene Infusion Bags, Int J Pharm Compound, vol.15, issue.6, pp.515-520, 2011.

M. Kupfer, G. Scriba, and M. Hartmann, Stability of alemtuzumab in infusion bags, Pharmazie, vol.64, issue.9, pp.622-623, 2009.

H. Autorité and D. Santé, Etats des lieux : Niveau de preuve et gradation des recommandations de bonne pratique, 2013.

A. Nationale-d, Accréditation et d'Evaluation en Santé. Guide d'analyse de la littérature et gradation des recommandations, 2000.

S. Figon and S. Erpeldinger, Recommandations, niveaux de preuve, EBM et décision médicale, 2013.

M. Criton, Les systèmes de notation. Tangente éducation, pp.1-5, 2008.

H. Mahler, R. Muller, W. Friess, A. Delille, and S. Matheus, Induction and analysis of aggregates in a liquid IgG1-antibody formulation, European Journal of Pharmaceutics and Biopharmaceutics, vol.59, issue.3, pp.407-417, 2005.
DOI : 10.1016/j.ejpb.2004.12.004

J. Balthasar, Concentration-dependent incompatibility of vinorelbine tartrate and heparin sodium

R. Dorr and J. Liddil, Stability of mitomycin C in different infusion fluids: Compatibility with heparin and glucocorticosteroids, Journal of Oncology Pharmacy Practice, vol.15, issue.3, pp.19-24, 1995.
DOI : 10.1007/BF02280051

L. Stolk, A. Fruijtier, and R. Umans, Stability after freezing and thawing of solutions of mitomycin C in plastic minibags for intravesical use, Pharmaceutisch Weekblad Scientific Edition, vol.43, issue.6, pp.286-288, 1986.
DOI : 10.1007/BF01959778

V. Mazzarelli, M. Ottiero, and M. Scalfaro, An NMR Study of the Bortezomib Degradation under Clinical Use Conditions. Advance in Haematology, p.5, 2009.

E. Quebbeman, A. Hamid, N. Hoffman, and R. Ausman, Stability of fluorouracil in plastic containers used for continuous infusion at home, Am J Hosp Pharm, vol.41, pp.1153-1156, 1984.

Y. Zhang, Q. Xu, L. Trissel, D. Gilbert, and F. Martinez, Compatibility and Stability of Paclitaxel Combined with Cisplatin and with Carboplatin in Infusion Solutions, Annals of Pharmacotherapy, vol.50, issue.12, pp.1465-1470, 1997.
DOI : 10.1111/j.1365-2710.1994.tb01118.x

F. Baud-camus, S. Crauste-manciet, E. Klein, L. Richard, and D. Brossard, Stability of fluorouracil in polypropylene syringes and ethylene vinyl acetate infusion-pump reservoirs, Am J Health-Syst Pharm, vol.53, pp.1457-1458, 1996.

L. Keusters, L. Stolk, R. Umans, and P. Van-asten, Stability of solutions of doxorubicin and epirubicin in plastic minibags for intravesical use after storage at ???20?? C and thawing by microwave radiation, Pharmaceutisch Weekblad, vol.71, issue.3, pp.194-197, 1986.
DOI : 10.1007/BF01968712

J. Cradock, L. Kleinmann, and A. Rahman, Evaluation of some pharmaceutical aspects of intrathecal methotrexate sodium, cytarabine and hydrocortisone sodium succinate, Am J Hosp Pharm, vol.35, pp.402-406, 1978.

J. Burm, J. Choi, S. Jhee, A. Chin, R. Ulrich et al., Stability of paclitaxel and fluconazole during simulated Y-site administration, Am J Hosp Pharm, vol.51, pp.2704-2706, 1994.

C. Lieu, A. Chin, and M. Gill, Five-day stability of vinorelbine in 5% dextrose injection and in 0.9% sodium chloride injection at room temperature, Int J Pharm Compound, vol.3, pp.67-68, 1999.

J. Cazin, Stability study of fotemustine in PVC infusion bags and sets under various conditions using a stability-indicating high-performance liquid chromatographic assay, J Pharm Biomed Anal, vol.18, pp.373-381, 1998.

K. Glover, Z. Gennaro, L. Yadav, S. Demeule, B. Wong et al., Compatibility and stability of pertuzumab and trastuzumab admixtures in i.v. infusion bags for coadministration, J Pharm

J. Goldspiel, B. Goldspiel, G. Grimes, P. Yuan, and G. Potti, Stability of alemtuzumab solutions at room temperature, American Journal of Health-System Pharmacy, vol.70, issue.5, pp.439-442, 2013.
DOI : 10.2146/ajhp110632

Y. Zhang, L. Vermeulen, and J. Kolesar, Stability of stock and diluted rituximab, American Journal of Health-System Pharmacy, vol.70, issue.5, pp.436-438, 2013.
DOI : 10.2146/ajhp120035

URL : http://europepmc.org/articles/pmc3987107?pdf=render

J. Kolesar and L. Vermeulen, Assays for biological agents, American Journal of Health-System Pharmacy, vol.70, issue.13, p.1101, 2013.
DOI : 10.2146/ajhp130128